<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>10267202</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">37161077</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmc">10267202</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">1593</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1038/s41386-023-01593-5</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Demographic and clinical characteristics of the sample. Means ± standard deviations or N (%).</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical characteristics of the sample. Means ± standard deviations or <italic>N</italic> (%).</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristics</th><th>Total (<italic>N</italic> = 89)</th><th>Assigned Female at Birth (<italic>N</italic> = 69)</th><th>Assigned Male at Birth (<italic>N</italic> = 20)</th><th>Assigned Sex Diff.</th></tr></thead><tbody><tr><td>Age (years)</td><td>29.5 ± 8.6</td><td>28.35 ± 7.8</td><td>33.35 ± 10.24</td><td><italic>p</italic> = 0.022</td></tr><tr><td>Race/Ethnicity (%)</td><td/><td/><td/><td><italic>p</italic> = 0.533</td></tr><tr><td> Asian</td><td>7 (8%)</td><td>6 (9%)</td><td>1 (5%)</td><td/></tr><tr><td> Black</td><td>7 (8%)</td><td>7 (10%)</td><td>0</td><td/></tr><tr><td> Hispanic/Latino</td><td>6 (7%)</td><td>4 (6%)</td><td>2 (10%)</td><td/></tr><tr><td> Native American</td><td>1 (1%)</td><td>1 (1%)</td><td>0</td><td/></tr><tr><td> White</td><td>65 (73%)</td><td>50 (72%)</td><td>15 (75%)</td><td/></tr><tr><td> Bi-/multiracial</td><td>2 (2%)</td><td>1 (1%)</td><td>1 (5%)</td><td/></tr><tr><td> Missing</td><td>1 (1%)</td><td>0</td><td>1 (5%)</td><td/></tr><tr><td>Gender (%)</td><td/><td/><td/><td>-</td></tr><tr><td> Female</td><td>65 (73%)</td><td>65 (94%)</td><td>0</td><td/></tr><tr><td> Male</td><td>19 (21%)</td><td>0</td><td>19 (95%)</td><td/></tr><tr><td> Non-binary or gender non-conforming</td><td>5 (6%)</td><td>4 (6%)</td><td>1 (5%)</td><td/></tr><tr><td>Sex Assigned at Birth (female/male)</td><td>69/20</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Medication (%)</td><td/><td/><td/><td><italic>p</italic>’s &gt; 0.289</td></tr><tr><td> SSRI</td><td>24 (27%)</td><td>19 (28%)</td><td>5 (25%)</td><td/></tr><tr><td> Mood Stabilizer</td><td>7 (8%)</td><td>6 (9%)</td><td>1 (5%)</td><td/></tr><tr><td> Antipsychotic</td><td>1 (1%)</td><td>1 (1%)</td><td>0</td><td/></tr><tr><td> Benzodiazepine</td><td>6 (7%)</td><td>3 (4%)</td><td>3 (15%)</td><td/></tr><tr><td> SNRI</td><td>4 (5%)</td><td>4 (6%)</td><td>0</td><td/></tr><tr><td> Tricyclic</td><td>1 (1%)</td><td>1 (1%)</td><td>0</td><td/></tr><tr><td> Stimulant</td><td>8 (9%)</td><td>6 (9%)</td><td>2 (10%)</td><td/></tr><tr><td> Anti-hypertensive</td><td>3 (3%)</td><td>3 (4%)</td><td>0</td><td/></tr><tr><td> Atypical Antidepressant</td><td>8 (9%)</td><td>7 (10%)</td><td>1 (5%)</td><td/></tr><tr><td> Anxiolytic</td><td>6 (7%)</td><td>4 (6%)</td><td>2 (10%)</td><td/></tr><tr><td>PACAP (pM)</td><td>960.7 ± 766.9</td><td>1109.9 ± 786.9</td><td>445.9 ± 385.0</td><td><italic>p</italic> &lt; 0.001</td></tr><tr><td>PTSD Diagnosis (%)</td><td>59 (66.3%)</td><td>49 (71%)</td><td>10 (50%)</td><td><italic>p</italic> = 0.080</td></tr><tr><td>CAPS Total</td><td>29.0 ± 10.3</td><td>30.6 ± 10.1</td><td>23.3 ± 9.2</td><td><italic>p</italic> = 0.006</td></tr><tr><td>CAPS – Anxious Arousal</td><td>3.1 ± 2.0</td><td>3.4 ± 2.1</td><td>2.8 ± 1.9</td><td><italic>p</italic> = 0.505</td></tr><tr><td>CAPS – Startle Response</td><td>1.3 ± 1.2</td><td>1.4 ± 1.3</td><td>1.0 ± 1.1</td><td><italic>p</italic> = 0.189</td></tr><tr><td>LEC-5 Total</td><td>13.2 ± 8.3</td><td>12.8 ± 8.4</td><td>14.4 ± 7.9</td><td><italic>p</italic> = 0.472</td></tr></tbody></table><table-wrap-foot><p><italic>PACAP</italic> pituitary adenylate cyclase-activating polypeptide, <italic>CAPS</italic> Clinician Administered PTSD Scale for DSM-5, <italic>LEC-5</italic> Life Events Checklist for DSM-5.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical characteristics of the sample. Means ± standard deviations or N (%).</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Characteristics</th><th>Total (N = 89)</th><th>Assigned Female at Birth (N = 69)</th><th>Assigned Male at Birth (N = 20)</th><th>Assigned Sex Diff.</th></tr></thead><tbody><tr><td>Age (years)</td><td>29.5 ± 8.6</td><td>28.35 ± 7.8</td><td>33.35 ± 10.24</td><td>p = 0.022</td></tr><tr><td>Race/Ethnicity (%)</td><td/><td/><td/><td>p = 0.533</td></tr><tr><td> Asian</td><td>7 (8%)</td><td>6 (9%)</td><td>1 (5%)</td><td/></tr><tr><td> Black</td><td>7 (8%)</td><td>7 (10%)</td><td>0</td><td/></tr><tr><td> Hispanic/Latino</td><td>6 (7%)</td><td>4 (6%)</td><td>2 (10%)</td><td/></tr><tr><td> Native American</td><td>1 (1%)</td><td>1 (1%)</td><td>0</td><td/></tr><tr><td> White</td><td>65 (73%)</td><td>50 (72%)</td><td>15 (75%)</td><td/></tr><tr><td> Bi-/multiracial</td><td>2 (2%)</td><td>1 (1%)</td><td>1 (5%)</td><td/></tr><tr><td> Missing</td><td>1 (1%)</td><td>0</td><td>1 (5%)</td><td/></tr><tr><td>Gender (%)</td><td/><td/><td/><td>-</td></tr><tr><td> Female</td><td>65 (73%)</td><td>65 (94%)</td><td>0</td><td/></tr><tr><td> Male</td><td>19 (21%)</td><td>0</td><td>19 (95%)</td><td/></tr><tr><td> Non-binary or gender non-conforming</td><td>5 (6%)</td><td>4 (6%)</td><td>1 (5%)</td><td/></tr><tr><td>Sex Assigned at Birth (female/male)</td><td>69/20</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Medication (%)</td><td/><td/><td/><td>p’s &gt; 0.289</td></tr><tr><td> SSRI</td><td>24 (27%)</td><td>19 (28%)</td><td>5 (25%)</td><td/></tr><tr><td> Mood Stabilizer</td><td>7 (8%)</td><td>6 (9%)</td><td>1 (5%)</td><td/></tr><tr><td> Antipsychotic</td><td>1 (1%)</td><td>1 (1%)</td><td>0</td><td/></tr><tr><td> Benzodiazepine</td><td>6 (7%)</td><td>3 (4%)</td><td>3 (15%)</td><td/></tr><tr><td> SNRI</td><td>4 (5%)</td><td>4 (6%)</td><td>0</td><td/></tr><tr><td> Tricyclic</td><td>1 (1%)</td><td>1 (1%)</td><td>0</td><td/></tr><tr><td> Stimulant</td><td>8 (9%)</td><td>6 (9%)</td><td>2 (10%)</td><td/></tr><tr><td> Anti-hypertensive</td><td>3 (3%)</td><td>3 (4%)</td><td>0</td><td/></tr><tr><td> Atypical Antidepressant</td><td>8 (9%)</td><td>7 (10%)</td><td>1 (5%)</td><td/></tr><tr><td> Anxiolytic</td><td>6 (7%)</td><td>4 (6%)</td><td>2 (10%)</td><td/></tr><tr><td>PACAP (pM)</td><td>960.7 ± 766.9</td><td>1109.9 ± 786.9</td><td>445.9 ± 385.0</td><td>p &lt; 0.001</td></tr><tr><td>PTSD Diagnosis (%)</td><td>59 (66.3%)</td><td>49 (71%)</td><td>10 (50%)</td><td>p = 0.080</td></tr><tr><td>CAPS Total</td><td>29.0 ± 10.3</td><td>30.6 ± 10.1</td><td>23.3 ± 9.2</td><td>p = 0.006</td></tr><tr><td>CAPS – Anxious Arousal</td><td>3.1 ± 2.0</td><td>3.4 ± 2.1</td><td>2.8 ± 1.9</td><td>p = 0.505</td></tr><tr><td>CAPS – Startle Response</td><td>1.3 ± 1.2</td><td>1.4 ± 1.3</td><td>1.0 ± 1.1</td><td>p = 0.189</td></tr><tr><td>LEC-5 Total</td><td>13.2 ± 8.3</td><td>12.8 ± 8.4</td><td>14.4 ± 7.9</td><td>p = 0.472</td></tr></tbody></table></div>PACAP pituitary adenylate cyclase-activating polypeptide, CAPS Clinician Administered PTSD Scale for DSM-5, LEC-5 Life Events Checklist for DSM-5.</transformed-table></extracted-table></extracted-tables-set>